Evidence map›Paper›PMID 35690914›Full record

ArticleTransboundary and emerging diseases2022

Hepatitis E virus in the endangered Iberian lynx (Lynx pardinus).

Javier Caballero-Gómez, Antonio Rivero-Juarez, Irene Zorrilla, Guillermo López, Fernando Nájera, Rainer G Ulrich, Carmen Ruiz-Rubio, Javier Salcedo, Antonio Rivero, Jorge Paniagua and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Transboundary and emerging diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Rat hepatitis E virus (Emerging microbes & infections · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Puzzles for Hepatitis E Virus.Advances in experimental medicine and biology · 2023
    Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Javier Caballero-GómezGrupo de Virología Clínica y Zoonosis, Unidad de Enfermedades Infecciosas, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain.ORCID https://orcid.org/0000-0002-6241-3439
Antonio Rivero-JuarezGrupo de Virología Clínica y Zoonosis, Unidad de Enfermedades Infecciosas, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain.ORCID https://orcid.org/0000-0002-5813-6889
Irene ZorrillaCentro de Análisis y Diagnóstico de la Fauna Silvestre, Agencia de Medio Ambiente y Agua de Andalucía, Consejería de Agricultura, Ganadería, Pesca y Desarrollo Sostenible, Junta de Andalucía, Málaga, Spain.
Guillermo LópezCentro de Análisis y Diagnóstico de la Fauna Silvestre, Agencia de Medio Ambiente y Agua de Andalucía, Consejería de Agricultura, Ganadería, Pesca y Desarrollo Sostenible, Junta de Andalucía, Málaga, Spain.
Fernando NájeraDepartamento de Fisiología Animal, Facultad de Veterinaria, Universidad Complutense de Madrid, Madrid, Spain.
Rainer G UlrichInstitute of Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald-Insel Riems, Germany.ORCID https://orcid.org/0000-0002-5620-1528
Carmen Ruiz-RubioCentro de Análisis y Diagnóstico de la Fauna Silvestre, Agencia de Medio Ambiente y Agua de Andalucía, Consejería de Agricultura, Ganadería, Pesca y Desarrollo Sostenible, Junta de Andalucía, Málaga, Spain.
Javier SalcedoConsejería de Agricultura, Ganadera, Pesca y Desarrollo Sostenible. Junta de Andalucía, Sevilla, Spain.
Antonio RiveroGrupo de Virología Clínica y Zoonosis, Unidad de Enfermedades Infecciosas, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain.
Jorge PaniaguaGrupo de Investigación en Sanidad Animal y Zoonosis (GISAZ), Departamento de Sanidad Animal, Universidad de Córdoba, Córdoba, Spain.
Ignacio García-BocanegraGrupo de Investigación en Sanidad Animal y Zoonosis (GISAZ), Departamento de Sanidad Animal, Universidad de Córdoba, Córdoba, Spain.
Consejería de Agricultura, Pesca, Agua y Desarrollo Rural · ESInstituto de Salud Carlos III · ESFriedrich-Loeffler-Institut · DEUniversidad Complutense de Madrid · ESUniversity of Córdoba · ES

Funding

Fundación para la Investigación en Salud (FIS) del Instituto Carlos III PI19/00864Fundación para la Investigación en Salud (FIS) del Instituto Carlos III PI21/00793German Centre for Infection Research (DZIF), TTU 'Emerging infections' TTU 01.808_00Miguel Servet Research Contract by the Spanish Ministry of Science, Innovation and Universities CP18/00111Ministerio de Sanidad RD12/0017/0012Spanish Ministry of Science, Innovation and Universities FPU17/01319
6 · The paper itself

Abstract

Hepatitis E virus (HEV) is an emerging zoonotic pathogen in Europe. In the Iberian Peninsula, wild boar (Sus scrofa) is considered the main wildlife reservoir of HEV. This wild ungulate shares habitat and resources with other potential HEV carriers in Iberian Mediterranean ecosystems, although information about the role of such sympatric species in the HEV epidemiological cycle is still very limited. The aims of the present large-scale, long-term study were: (1) to determine the seroprevalence and prevalence of HEV in both free-living and captive populations of the Iberian lynx (Lynx pardinus), the most endangered felid in the world; (2) to determine potential risk factors associated with HEV exposure in this species and (3) to evaluate the dynamics of seropositivity in longitudinally sampled animals during the study period. Between 2010 and 2021, serum samples from 275 Iberian lynxes were collected in free-ranging and captive populations across the Iberian Peninsula. Forty-four of the 275 lynxes were also longitudinally sampled during the study period. A double-antigen sandwich ELISA was used to test for the presence of antibodies against HEV. A subset of seropositive samples was analysed by Western blot (WB) assay to confirm exposure to HEV. In addition, serum, liver and/or faecal samples from 367 individuals were tested for orthohepevirus RNA by RT-PCR. A total of 50 (18.2%; 95% CI: 14.1-23.2) of the 275 animals analysed had anti-HEV antibodies by ELISA. Exposure to HEV was confirmed by WB in most of the ELISA-positive Iberian lynxes analysed. Significantly higher seroprevalence was found in captive (33.6%) compared to free-ranging (7.4%) individuals. Within captive population, the GEE model identified 'age' (senile, adult and subadult) as risk a factor potentially associated with HEV exposure in the Iberian lynx. Thirteen (29.5%) of 44 longitudinally surveyed individuals seroconverted against HEV during the study period. HEV RNA was detected in the faeces of one (1/364; 0.3%; 95% CI: 0.0-0.8) free-ranging adult animal sampled in 2021. Phylogenetic analysis showed that the sequenced strain belongs to HEV-3f subtype and shared a high nucleotide sequence identity (97-99.6%) with human HEV-3f sequences from Spain and France. To the best of the authors' knowledge, this is the first survey study on HEV in the Iberian lynx and the first molecular report of HEV-A infection in free-ranging felines. Our results indicate high exposure to HEV-3 in Iberian lynx populations, particularly those kept in captivity. The serological results suggest widespread but not homogeneous circulation of HEV in Iberian lynx populations. Further studies are required to assess the epidemiological role of this endangered species as a potential spillover host of HEV.

Indexed as

Cat DiseasesHepatitis EHepatitis E virusLynxAnimalsCatsEcosystemHumansPhylogenyRNASeroepidemiologic StudiesSpainRNAepidemiologyhepatitis EHEV-3fIberian lynxrisk factors

Identifiers

PMID35690914
PMCPMC9796619
OpenAlexW4282599986

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.